P. Kaiser

Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.

G. Demetri, M. von Mehren, J. Hamm, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Overall survival and histology‐specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma

G. Demetri, R. Maki, M. von Mehren, 2019, Cancer.

Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate‐grade or high‐grade liposarcoma

E. Stepanski, M. Milhem, D. Priebat, 2017, Cancer.

3403 Final overall survival (OS) analysis of the randomized phase 3 study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS)

G. Demetri, R. Maki, J. Hamm, 2015 .

Sunitinib for patients (pts) with advanced imatinib (IM)-refractory GIST: Early results from a "treatment-use" trial.

G. Demetri, H. Hurwitz, C. Baum, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment‐use trial of sunitinib

G. Demetri, H. Hurwitz, Yoon-Koo Kang, 2015, Cancer.

Phase I report from a multicenter trial of perifosine (PERI) + sunitinib (SUT) in patients with advanced cancers including renal cell carcinoma (RCC)

I. Henderson, S. Chawla, R. Birch, 2008 .

Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines.

M. Scheinbaum, P. Kaiser, P. Kaiser, 1998 .

Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines.

M. Scheinbaum, P. Kaiser, J. Cole, 1998, Journal of clinical psychopharmacology.